Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.

@article{Gornet2003InfliximabFR,
  title={Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.},
  author={J M Gornet and Sophie Couv{\'e} and Zahir Hassani and J-C Delchier and Philippe Marteau and Jacques Cosnes and Yoram Bouhnik and J L Dupas and Robert Modigliani and François Taillard and Marc L{\'e}mann},
  journal={Alimentary pharmacology & therapeutics},
  year={2003},
  volume={18 2},
  pages={175-81}
}
BACKGROUND The efficacy of infliximab in ulcerative colitis (UC) and indeterminate colitis has been poorly assessed and preliminary results are conflicting. METHODS The records of 30 patients treated with infliximab for ulcerative colitis (n=19) or indeterminate colitis (n=11) were reviewed. Infliximab was given because of steroid resistance (n=18), dependence (n=5) or intolerance (n=7); five patients had failed on cyclosporin; 19 patients had a severe flare-up. RESULTS Median duration of… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Infliximab was given because of steroid resistance ( n=18 ) , dependence ( n=5 ) or intolerance ( n=7 ) ; five patients had failed on cyclosporin ; 19 patients had a severe flare - up .
Infliximab was given because of steroid resistance ( n=18 ) , dependence ( n=5 ) or intolerance ( n=7 ) ; five patients had failed on cyclosporin ; 19 patients had a severe flare - up .
All Topics